FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2003029412> ?p ?o ?g. }

• W2003029412 abstract "Abstract Background Prognostic factors in locally advanced breast cancer treated with neoadjuvant chemotherapy differ from those of early breast cancer. The purpose of this study was to identify the clinical significance of potential predictive and prognostic factors in breast cancer patients treated by neoadjuvant chemotherapy. Methods A total of 145 stage II and III breast cancer patients received neoadjuvant docetaxel/doxorubicin chemotherapy were enrolled in this study. We examined the clinical and biological factors (ER, PR, p53, c-erbB2, bcl-2, and Ki-67) by immunohistochemistry. We analyzed clinical outcome and their correlation with clinicopathologic parameters. Results Among the clinicopathologic parameters investigated, none of the marker was correlated with response rate (RR) except triple negative phenotype. Patients with triple negative phenotype showed higher RR (83.0% in triple negative vs . 62.2% in non-triple negative, p = 0.012) and pathologic complete RR (17.0% in triple negative vs . 3.1% in non-triple negative, p = 0.005). However, relapse free survival (RFS) and overall survival (OS) were significantly shorter in triple negative breast cancer patients ( p < 0.001, p = 0.021, respectively). Low histologic grade, positive hormone receptors, positive bcl-2 and low level of Ki-67 were associated with prolonged RFS. In addition, positive ER and positive bcl-2 were associated with prolonged OS. In our homogeneous patient population, initial clinical stage reflects RFS and OS more precisely than pathologic stage. In multivariate analysis, initial clinical stage was the only significant independent prognostic factor to impact on OS (hazard ratio 3.597, p = 0.044). Conclusion Several molecular markers provided useful predictive and prognostic information in stage II and III breast cancer patients treated with neoadjuvant docetaxel/doxorubicin chemotherapy. Triple negative phenotype was associated with shorter survival, even though it was associated with a higher response rate to neoadjuvant chemotherapy." @default.
• W2003029412 created "2016-06-24" @default.
• W2003029412 creator A5005022842 @default.
• W2003029412 creator A5006038043 @default.
• W2003029412 creator A5009933828 @default.
• W2003029412 creator A5012153148 @default.
• W2003029412 creator A5013664294 @default.
• W2003029412 creator A5019037704 @default.
• W2003029412 creator A5024891671 @default.
• W2003029412 creator A5027426063 @default.
• W2003029412 creator A5042401127 @default.
• W2003029412 creator A5049125652 @default.
• W2003029412 creator A5050684671 @default.
• W2003029412 creator A5059766169 @default.
• W2003029412 creator A5066161983 @default.
• W2003029412 creator A5069050806 @default.
• W2003029412 creator A5081513988 @default.
• W2003029412 creator A5089784777 @default.
• W2003029412 date "2007-11-01" @default.
• W2003029412 modified "2023-10-16" @default.
• W2003029412 title "Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer" @default.
• W2003029412 cites W1932878073 @default.
• W2003029412 cites W1972090515 @default.
• W2003029412 cites W1979237833 @default.
• W2003029412 cites W1989663680 @default.
• W2003029412 cites W1995522725 @default.
• W2003029412 cites W2000885291 @default.
• W2003029412 cites W2001646586 @default.
• W2003029412 cites W2010871781 @default.
• W2003029412 cites W2013920437 @default.
• W2003029412 cites W2048045188 @default.
• W2003029412 cites W2059701501 @default.
• W2003029412 cites W2061259042 @default.
• W2003029412 cites W2082803176 @default.
• W2003029412 cites W2109462843 @default.
• W2003029412 cites W2122035649 @default.
• W2003029412 cites W2122761438 @default.
• W2003029412 cites W2130000923 @default.
• W2003029412 cites W2131686669 @default.
• W2003029412 cites W2131994307 @default.
• W2003029412 cites W2133764807 @default.
• W2003029412 cites W2138929540 @default.
• W2003029412 cites W2139248078 @default.
• W2003029412 cites W2139510434 @default.
• W2003029412 cites W2143336748 @default.
• W2003029412 cites W2151552922 @default.
• W2003029412 cites W2154142993 @default.
• W2003029412 cites W2157219527 @default.
• W2003029412 cites W2157285286 @default.
• W2003029412 cites W2162760540 @default.
• W2003029412 cites W2164361217 @default.
• W2003029412 cites W2164774797 @default.
• W2003029412 cites W2165371109 @default.
• W2003029412 cites W2165608465 @default.
• W2003029412 cites W2287271371 @default.
• W2003029412 cites W29671035 @default.
• W2003029412 cites W4239180165 @default.
• W2003029412 cites W4378590823 @default.
• W2003029412 doi "https://doi.org/10.1186/1471-2407-7-203" @default.
• W2003029412 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2217558" @default.
• W2003029412 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17976237" @default.
• W2003029412 hasPublicationYear "2007" @default.
• W2003029412 type Work @default.
• W2003029412 sameAs 2003029412 @default.
• W2003029412 citedByCount "137" @default.
• W2003029412 countsByYear W20030294122012 @default.
• W2003029412 countsByYear W20030294122013 @default.
• W2003029412 countsByYear W20030294122014 @default.
• W2003029412 countsByYear W20030294122015 @default.
• W2003029412 countsByYear W20030294122016 @default.
• W2003029412 countsByYear W20030294122017 @default.
• W2003029412 countsByYear W20030294122018 @default.
• W2003029412 countsByYear W20030294122019 @default.
• W2003029412 countsByYear W20030294122020 @default.
• W2003029412 countsByYear W20030294122021 @default.
• W2003029412 countsByYear W20030294122022 @default.
• W2003029412 countsByYear W20030294122023 @default.
• W2003029412 crossrefType "journal-article" @default.
• W2003029412 hasAuthorship W2003029412A5005022842 @default.
• W2003029412 hasAuthorship W2003029412A5006038043 @default.
• W2003029412 hasAuthorship W2003029412A5009933828 @default.
• W2003029412 hasAuthorship W2003029412A5012153148 @default.
• W2003029412 hasAuthorship W2003029412A5013664294 @default.
• W2003029412 hasAuthorship W2003029412A5019037704 @default.
• W2003029412 hasAuthorship W2003029412A5024891671 @default.
• W2003029412 hasAuthorship W2003029412A5027426063 @default.
• W2003029412 hasAuthorship W2003029412A5042401127 @default.
• W2003029412 hasAuthorship W2003029412A5049125652 @default.
• W2003029412 hasAuthorship W2003029412A5050684671 @default.
• W2003029412 hasAuthorship W2003029412A5059766169 @default.
• W2003029412 hasAuthorship W2003029412A5066161983 @default.
• W2003029412 hasAuthorship W2003029412A5069050806 @default.
• W2003029412 hasAuthorship W2003029412A5081513988 @default.
• W2003029412 hasAuthorship W2003029412A5089784777 @default.
• W2003029412 hasBestOaLocation W20030294121 @default.
• W2003029412 hasConcept C121608353 @default.
• W2003029412 hasConcept C126322002 @default.
• W2003029412 hasConcept C143998085 @default.
• W2003029412 hasConcept C146357865 @default.
• W2003029412 hasConcept C151730666 @default.

• next